Original ArticleEffusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma
Under an Elsevier user license
open archive
Key Words
Non–small-cell lung cancer (NSCLC)
Epidermal growth factor receptor (EGFR)
Mutation
Malignant pleural effusion
Immunocytochemistry
Cited by (0)
Tzu-Hsiu Tsai and Shang-Gin Wu contributed equally to this work.
This study was performed at National Taiwan University Hospital, Taipei, Taiwan
Disclosure: Dr. Chih-Hsin Yang received honoraria from AstraZeneca and Roche for speeches and being a member of its ad hoc advisory committee. Drs. Chong-Jen Yu and Jin-Yuan Shih received honoraria from AstraZeneca and Roche for speeches. All other authors report no conflicts of interest.
Copyright © 2012 International Association for the Study of Lung Cancer. All rights reserved.